Invicta Diagnostic IPO Subscription Status

Invicta Diagnostic IPO subscription started on 1 December, 2025 and will close on 3 December, 2025. The retail quota is 35%, QIB is 50% and NII is 15%. Invicta Diagnostic IPO got a lot of interest, raising around ₹33,08,800 shares (aggregating up to ₹28.12 Cr) Crores, with subscriptions 4.27 times overall, including 3.51 times by institutional investors, 6.96 times by non-institutional investors, and 3.44 times by retail investors. Shares are priced between ₹₹80 to ₹85 per share each and will be listed on the NSE.
  Check Live IPO  Subscription List  👈
Listed
Last Updated - December 3, 2025 11:55 pm

Invicta Diagnostic IPO Subscription - Day 3

QIB - Qualified Institutional Buyers: 3.51x
NII - Non-Institutional Investors: 6.96x
SNII - Small Non-Institutional Investors: [.]x
BNII - Big Non-Institutional Investors: [.]x
RII - Retail Individual Investor: 3.44x
Total: 4.27x 👈

Invicta Diagnostic IPO Investor Categories

  • Qualified Institutional Buyers: QIB
  • Non-Institutional Investors: NII
  • Small Non-Institutional Investors: SNII- Bid below ₹10L
  • Big Non-Institutional Investors: BNII- Bid above ₹10L
  • Retail Individual Investor: RII
  • Employees Quota: EMP

Invicta Diagnostic IPO Dates

IPO Activity Date
Open Date: 1 December, 2025
Close Date: 3 December, 2025
Allotment Date: 4 December, 2025
Refund Date: 5 December, 2025
Shares Credit Date: 5 December, 2025
Listing Date: 8 December, 2025

Invicta Diagnostic IPO Subscription Status FAQs

Q.When Invicta Diagnostic IPO Subscription will start?

Ans.The IPO subscription starts on 1 December, 2025 for Investors.


Q.What is the Invicta Diagnostic IPO Subscription last date?

Ans.Invicta Diagnostic IPO subscription last date is 3 December, 2025 for Investors.


Q.What is the Invicta Diagnostic IPO Allotment Date?

Ans.Invicta Diagnostic IPO allotment date is 4 December, 2025.


Q.What is the Invicta Diagnostic IPO Listing Date?

Ans.Invicta Diagnostic IPO listing date is 8 December, 2025. The IPO is to list on NSE.